Cytek Biosciences (NASDAQ:CTKB) Announces Quarterly Earnings Results, Misses Estimates By $0.36 EPS

Cytek Biosciences (NASDAQ:CTKB) issued its quarterly earnings data on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.36), FiscalAI reports. Cytek Biosciences had a negative net margin of 6.51% and a negative return on equity of 3.35%. The firm had revenue of $62.14 million for the quarter, compared to analyst estimates of $58.80 million.

Here are the key takeaways from Cytek Biosciences’ conference call:

• Q4 revenue reached $62.1 million (+8% YoY) — the company’s highest quarterly revenue ever — and full-year 2025 revenue was $201.5 million (+1% YoY) after acceleration in the second half of the year.
• Recurring revenue strengthened meaningfully, representing 34% of total revenue and growing 21% YoY, while Cytek Cloud users exceeded 24,000 (over 50% growth), supporting product stickiness and reagent uptake.
• Product traction broadened: installed base rose to 3,664 units (+208 in Q4), the Aurora Evo and Muse Micro showed strong early adoption, and reagent revenue grew >20% in Q4 (>25% for the year).
• Profitability was pressured as GAAP gross margin fell to 52% and operating expenses increased (notably higher G&A from legal/patent costs), resulting in a 2025 GAAP net loss of $66.5 million that included a large, non‑cash deferred tax valuation allowance.
• Management guided 2026 revenue of $205M–$212M (≈2%–5% growth), expects continued positive adjusted EBITDA, and highlighted operational moves (new Singapore manufacturing site went live quickly) to support growth and supply resilience.

Cytek Biosciences Stock Up 1.8%

Shares of CTKB stock traded up $0.08 on Friday, reaching $4.48. The stock had a trading volume of 1,398,770 shares, compared to its average volume of 851,266. The firm’s 50-day moving average is $4.96 and its two-hundred day moving average is $4.55. The firm has a market capitalization of $572.81 million, a price-to-earnings ratio of -44.80 and a beta of 1.30. Cytek Biosciences has a 12 month low of $2.37 and a 12 month high of $6.18.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. TD Cowen reissued a “buy” rating on shares of Cytek Biosciences in a report on Thursday, January 8th. Piper Sandler reduced their target price on Cytek Biosciences from $8.00 to $7.50 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Cytek Biosciences in a report on Monday, December 29th. Zacks Research lowered Cytek Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Finally, Morgan Stanley assumed coverage on shares of Cytek Biosciences in a report on Monday, December 1st. They issued an “equal weight” rating and a $6.00 price target for the company. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $5.50.

Hedge Funds Weigh In On Cytek Biosciences

Several large investors have recently modified their holdings of CTKB. Intech Investment Management LLC lifted its holdings in Cytek Biosciences by 6.7% during the 4th quarter. Intech Investment Management LLC now owns 51,740 shares of the company’s stock worth $261,000 after purchasing an additional 3,242 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Cytek Biosciences by 4.6% in the fourth quarter. Deutsche Bank AG now owns 93,139 shares of the company’s stock valued at $470,000 after acquiring an additional 4,119 shares in the last quarter. Federated Hermes Inc. increased its position in Cytek Biosciences by 150.9% during the second quarter. Federated Hermes Inc. now owns 7,221 shares of the company’s stock worth $25,000 after acquiring an additional 4,343 shares during the period. Prudential Financial Inc. raised its stake in Cytek Biosciences by 5.9% in the 2nd quarter. Prudential Financial Inc. now owns 112,667 shares of the company’s stock worth $383,000 after purchasing an additional 6,285 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in Cytek Biosciences by 2.0% in the 2nd quarter. Invesco Ltd. now owns 343,659 shares of the company’s stock valued at $1,168,000 after purchasing an additional 6,706 shares during the period. 69.46% of the stock is owned by institutional investors.

About Cytek Biosciences

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.